688139 海尔生物
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,782,020-2.43%2,280,8962,864,0452,125,8631,402,029
减:营业总成本1,468,536-3.93%1,966,9372,293,3961,688,3161,082,247
    其中:营业成本917,520-1.47%1,125,9781,484,8811,059,842694,110
               财务费用(33,895)127.60%(23,532)(20,279)(11,883)(14,367)
               资产减值损失(1,755)20.23%(1,643)(5,410)(1,328)(1,360)
公允价值变动收益(173)-95.81%2,056(7,007)10,2083,831
投资收益16,606-77.36%83,03374,721473,26789,962
    其中:对联营企业和合营企业的投资收益4,50615.49%8,1738,96314,19326,828
营业利润340,805-13.76%438,401675,680961,434427,548
利润总额342,418-12.56%434,491675,336960,871424,236
减:所得税费用23,441-9.76%22,43363,362111,70140,112
净利润318,978-12.76%412,059611,974849,170384,123
减:非控股权益9,83616.48%5,98511,1834,1353,169
股东净利润309,142-13.45%406,074600,791845,035380,954

市场价值指针
每股收益 (元) *0.980-13.27%1.2801.8902.6701.200
每股派息 (元) *----0.5150.4500.5000.380
每股净资产 (元) *13.5292.24%13.30612.64511.4268.755
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容